ROSSARI

Rossari Biotech share price & financials

Specialty chemicals maker for home & personal care, textiles and animal health, built via Unitop and Tristar acquisitions.

Price: ₹560.9
Market cap: ₹2.7k Cr
Sector: Chemicals
Calls analysed: 8

Latest concall · Q1 FY27 · call held 20 Jul 2026

Rossari Biotech Limited Q1 FY27

Revenue from Operations ₹697.2 cr +28%EBITDA ₹80.6 cr +19%EBITDA Margin 11.6% PAT ₹35.1 cr +5%

What went well

Achieved highest ever quarterly revenue of ₹697.2 crores, marking a 28% YoY growth.
Recorded highest ever quarterly EBITDA of ₹80.6 crores, an 18.7% YoY increase.
All core business segments (HPPC, TSC, AHN) demonstrated strong growth of approximately 28% YoY.

What to watch

EBITDA margin declined to 11.6% in Q1 FY27 from 12.5% in Q1 FY26.
Institutional and consumer businesses remained subdued, impacting overall profitability.

Read the full call →

What Rossari Biotech Limited does

Rossari Biotech manufactures specialty chemical formulations - surfactants, ethoxylates, enzymes, textile auxiliaries and animal-feed additives - sold to industrial and institutional customers in India and abroad. It operates through three reported businesses (HPPC, TSC and AHN) and two acquired manufacturing subsidiaries, Unitop Chemicals (surfactants, ethoxylates, agrochemical and oil & gas chemicals) and Tristar Intermediates (preservatives, aroma chemicals and distillation-based specialty ingredients). Products are manufactured at plants in Dahej and Silvassa (Gujarat/Dadra & Nagar Haveli) and Sarigam, and sold domestically as well as exported, supported by in-house R&D centres that develop new formulations.

Segments

HPPC (Home, Personal Care and Performance Chemicals)
TSC (Textile Specialty Chemicals)
AHN (Animal Health and Nutrition)

Manufacturing facilities: 7, across Dahej (Rossari and Unitop plants), Silvassa (Rossari) and Sarigam (Tristar, 3 units)
Total installed manufacturing capacity: 382,100 MTPA (including production capacity of subsidiaries Unitop and Tristar)
R&D facilities: 4, including a new consolidated R&D facility at Koparkhairane, Navi Mumbai that replaced the earlier IIT Bombay campus lab
Export footprint: Export operations in 80 countries
Product formulations/SKUs: 4,300+ formulations across HPPC, TSC and AHN divisions
Customer base: 3,010+ total customers (HPPC 1,750+, TSC 1,000+, AHN 125+)

Founded 2003 Company website

Guidance record · Q1 FY27

what the last two calls moved 21 tracked 2 delivered 2 missed 17 open

Core B2B EBITDA Margin delivered, diluted said Q2 FY26 Promised: 14% - 16% Q1 FY27: Core B2B EBITDA margin for Q1 FY27 was reported at 14.0%, continuing the trend of meeting only the absolute low end of the guided range.
Institutional Cleaning Sales (FY25) delivered said Q2 FY25 Promised: ₹250 crores Q1 FY27: This promise pertains to a prior fiscal year and is considered closed.
Institutional Cleaning Sales (2-Year Target) revised down said Q3 FY25 Promised: Rs. 450 – Rs. 500 crore in 2 years Q1 FY27: Management is actively rationalizing the B2C business, which was part of the institutional segment, making the original target of doubling the business strategically obsolete and unachievable.

All 21 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 28.1%, net profit up 2.9% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	498	513	580	544	586 +18%	582 +13%	685 +18%	697 +28%
Expenses	432	448	510	476	514	513	608	617
EBITDA	66	65	69	68	72 +9%	69 +6%	77 +12%	81 +19%
Margin	13%	13%	12%	12%	12%	12%	11%	12%
Other income	1	1	2	2	2	1	20	4
Interest	4	5	6	6	6	8	9	11
Depreciation	15	18	18	18	18	20	24	26
Profit before tax	48	42	48	46	50 +4%	43 +2%	64 +33%	48 +4%
Tax rate	27%	25%	28%	27%	26%	23%	28%	26%
Net profit	35	32	34	34	37 +6%	33 +3%	46 +35%	35 +3%
EPS	6.39	5.73	6.22	6.07	6.66	5.92	8.30	6.34

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −29.6% 1Y

1Y: ₹633.45 on 10 Sept 2025 → ₹446.15. High ₹675.05 (19 Sept 2025), low ₹378.6 (30 Mar 2026).

How the price took the results

close before → close after

Q1 FY27: −2.4%; 20 Jul
Q4 FY26: −7.0%; 28 Apr
Q3 FY26: −2.5%; 19 Jan
Q2 FY26: −0.2%; 17 Oct

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 13.1% a year over 3 years, FY23 to FY26. Operating margin narrowed to 11.9%.

Year ending	FY23	FY24	FY25	FY26
Revenue	₹1.7k Cr	₹1.8k Cr	₹2.1k Cr	₹2.4k Cr
Operating profit	₹224 Cr	₹250 Cr	₹265 Cr	₹286 Cr
Operating margin	13.5%	13.7%	12.7%	11.9%
Interest	₹22 Cr	₹18 Cr	₹19 Cr	₹29 Cr
Depreciation	₹63 Cr	₹60 Cr	₹66 Cr	₹80 Cr
Net profit	₹108 Cr	₹130 Cr	₹136 Cr	₹150 Cr
Net margin	6.5%	7.1%	6.5%	6.3%
ROCE	18.0%	18.0%	16.0%	13.0%

How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year ending	FY21	FY22	FY23	FY24	FY25	FY26
Equity capital	₹10 Cr	₹11 Cr	₹11 Cr	₹11 Cr	₹11 Cr	₹11 Cr
Reserves	₹398 Cr	₹794 Cr	₹904 Cr	₹1.0k Cr	₹1.2k Cr	₹1.3k Cr
Borrowings	₹0 Cr	₹8 Cr	₹74 Cr	₹119 Cr	₹353 Cr	₹436 Cr
Other liabilities	₹152 Cr	₹442 Cr	₹375 Cr	₹401 Cr	₹484 Cr	₹505 Cr
Total liabilities	₹561 Cr	₹1.3k Cr	₹1.4k Cr	₹1.6k Cr	₹2.1k Cr	₹2.3k Cr
Fixed assets	₹181 Cr	₹607 Cr	₹585 Cr	₹578 Cr	₹630 Cr	₹784 Cr
Capital work in progress	₹0 Cr	₹1 Cr	₹16 Cr	₹47 Cr	₹247 Cr	₹173 Cr
Investments	₹0 Cr	₹36 Cr	₹51 Cr	₹63 Cr	₹20 Cr	₹62 Cr
Other assets	₹379 Cr	₹611 Cr	₹712 Cr	₹880 Cr	₹1.2k Cr	₹1.3k Cr
Total assets	₹561 Cr	₹1.3k Cr	₹1.4k Cr	₹1.6k Cr	₹2.1k Cr	₹2.3k Cr

How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

What the price assumes

Expensive

To justify its price of ₹446, this stock must grow earnings at 11% every year for 7 years. Our analysis caps realistic growth at ~7%. At that growth it is worth ₹343 — downside of 23%.

Growth the price implies: 11.4% a year; for 7 years, fading to 4%
It has actually compounded at: 6.6% a year; net profit, FY23–FY26 · EPS 6.5%
The gap: 0.0 pp; -23% downside if it only repeats history

Price today ₹446.15 Value at the reference growth ₹342.9

Change the assumptions yourself →

All earnings calls (7)

Read the Q1 FY27 call →

Learn to analyse Rossari Biotech Limited

Guides on how to read this kind of business and the numbers that matter.